Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    Asenapine, Olanzapine Effective in Patients With Bipolar 1 Disorder: Presented at WCBP - (DGDispatch)
    FDA: Boxed Warning Required for Varenicline, Buproprion Due to Risk of Suicidal Behaviour - (DGNews)
    Quetiapine Monotherapy Shows Potential in Post-Traumatic Stress Disorder: Presented at WCBP - (DGDispatch)
    Olanzapine Effective for Bipolar Disorder in Naturalistic Setting: Presented at WCBP - (DGDispatch)
    Study Suggests Irritability Should Be Considered When Diagnosing Bipolar Disorder in Children - (DGNews)

    News archive

     Recent webcasts/CME - Psychiatry Other
      A Guide to Advances in Pain Management: A Synopsis of Roundtable Discussions
      Recognizing and Managing Psychotic and Mood Disorders in Primary Care
      Challenges of the Comorbid Patient: Evaluating Common Comorbidities in Adults and Children/Adolescents and Treatment Considerations
      Mixed States: Practical Application of Evidence, Guidelines, and Clinical Judgment
      Hypomania: The Clinical Reality of Diagnosing Adult and Child/Adolescent Patients

      Webcasts/CME archive

       Recent cases - Psychiatry Other
        Female Sexual Dysfunction as a Comorbid Illness
        11p Microdeletion Including WT1 but not PAX6, Presenting with Cataract, Mental Retardation, Genital Abnormalities and Seizures: Case Report
        Comorbidity of Asperger's Syndrome and Bipolar Disorder
        Psychiatric Disorder Associated with Vacuum-Assisted Breast Biopsy Clip Placement: A Case Report
        Treating Bipolar Disorder in Patients with Renal Failure Having Haemodialysis: Two Case Reports

        Cases archive
          




        my personal edition > psychiatry other > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Risk Of Suicide Attempt and Death Higher With Divalproex Than With Lithium In Patients With Bipolar Disorder

        A DGReview of :"Suicide Risk in Bipolar Disorder During Treatment With Lithium and Divalproex"
        Journal of the American Medical Association (JAMA)

        10/13/2003
        By Emma Hitt, PhD


        Among patients being treated for bipolar disorder, the risk of suicide attempts and deaths is 1.5 to 3 times higher with divalproex than with lithium treatment, say researchers.

        Several studies have suggested that lithium reduces suicide risk in patients with bipolar disorder; however, the risk with divalproex, the most commonly prescribed mood-stabilizing drug in the United States, has not been examined.

        Frederick K. Goodwin, MD, with Department of Psychiatry at George Washington University Medical Center, Washington, DC, and colleagues analysed data from participants in 2 large integrated health plans in California and Washington.

        The population-based sample included 20,638 health plan members, aged 14 years or older, who had at least 1 outpatient diagnosis of bipolar disorder and at least 1 filled prescription for lithium, divalproex, or carbamazepine between January 1, 1994, and December 31, 2001.

        For both health plans, unadjusted rates were significantly higher during treatment with divalproex than with lithium for emergency department suicide attempt (p < 0.001), suicide attempt resulting in hospitalisation (p < 0.001), and suicide death (p = 0.04).

        After adjustment for confounding factors, risk of suicide death was 2.7 times higher (p = 0.03) during treatment with divalproex than with lithium. Corresponding hazard ratios for nonfatal attempts were 1.7 (p = 0.002) for attempts resulting in hospitalisation and 1.8 (p < 0.001) for attempts diagnosed in the emergency department.

        "This difference in risk was consistent across all outcome measures...and across the 2 study sites," the authors point out. They add that results for carbamazepine were similar to those of divalproex but perhaps less precise due to the sample size.

        Dr. Goodwin and colleagues point out that "many psychiatric residents have no or limited experience prescribing lithium, largely a reflection of the enormous focus on the newer drugs in educational programs supported by the pharmaceutical industry."

        "If lithium does have an anti-suicide effect not matched by currently available alternatives, then current prescribing patterns should be re-evaluated," they add.
        JAMA. 2003;290:1467-1473. "Suicide Risk in Bipolar Disorder During Treatment With Lithium and Divalproex"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send